Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Notes Payables (2014 - 2017)

Bio-Techne's quarterly Notes Payables came in at $14.6 million in Q1 2017, up 282.83% year-on-year from $3.8 million in Q1 2016, and up 305.51% quarter-over-quarter from $3.6 million in Q4 2016.

Bio-Techne has reported Notes Payables for 4 years, with the latest figure at $14.6 million in Q1 2017.

  • For the quarter ending Q1 2017, Notes Payables rose 282.83% year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2017 stood at $14.6 million (up 282.83% YoY), and the FY2016 full-year result was $3.8 million, down 6.59% from the prior year.
  • Notes Payables for Q1 2017 stood at $14.6 million, up from $3.6 million in the prior quarter.
  • The five-year high for Notes Payables was $14.6 million in Q1 2017, with the low at $3.0 million in Q1 2015.
  • Average Notes Payables over 4 years is $5.2 million, with a median of $3.8 million recorded in 2015.
  • Year-over-year, Notes Payables sank 36.67% in 2015 and soared 282.83% in 2017.
  • Tracing TECH's Notes Payables over 4 years: stood at $6.0 million in 2014, then slumped by 36.67% to $3.8 million in 2015, then dropped by 5.12% to $3.6 million in 2016, then soared by 305.51% to $14.6 million in 2017.
  • The last three Notes Payables figures came in at $14.6 million (Q1 2017), $3.6 million (Q4 2016), and $3.7 million (Q3 2016), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2017 14.58 Mn
Dec 31, 2016 3.60 Mn
Sep 30, 2016 3.73 Mn
Jun 30, 2016 3.76 Mn
Mar 31, 2016 3.81 Mn
Dec 31, 2015 3.79 Mn
Sep 30, 2015 3.87 Mn
Jun 30, 2015 4.02 Mn
Mar 31, 2015 3.00 Mn
Dec 31, 2014 5.98 Mn
Sep 30, 2014 5.95 Mn
Jun 30, 2014 5.95 Mn